Chromos gains licence from Lonza Biologics for production host cell line
Canadian biotechnology company Chromos Molecular Systems has entered into a licence agreement with contract protein manufacturer, Lonza Biologics, of Slough in the UK, whereby Chromos has acquired non-exclusive rights to employ Lonza's proprietary CHOK1SV cell line in combination with Chromos' proprietary ACE System for cellular protein production applications.
Canadian biotechnology company Chromos Molecular Systems has entered into a licence agreement with contract protein manufacturer, Lonza Biologics, of Slough in the UK, whereby Chromos has acquired non-exclusive rights to employ Lonza's proprietary CHOK1SV cell line in combination with Chromos' proprietary ACE System for cellular protein production applications.
Chromos has the rights to use this combination to engineer production quality cell lines for third parties. In addition, Chromos will have the right to grant sub-licenses to third parties to use the combined technologies for the development of biopharmaceutical products such as recombinant proteins and monoclonal antibodies. Chromos will pay Lonza a portion of its sub-licensing revenues as consideration for using its cell line. No further financial details have been disclosed.
The CHOK1SV cell line has been generated in compliance with GMP guidelines, thereby accelerating Chromos' ability to provide a more attractive production system to its partners for the production of biopharmaceuticals